Carlos H. Lopes

Sao Paulo, SP, Brazil

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Longitudinal validation of ENLIGHT, an AI predictor of immunotherapy response and resistance, in pan-cancer cohorts.

Longitudinal validation of ENLIGHT, an AI predictor of immunotherapy response and resistance, in pan-cancer cohorts.

Journal: NPJ precision oncology

Published: January 26, 2026

Development and Validation of an Intratumor Heterogeneity-Based Prognostic Model for Clear Cell Renal Cell Carcinoma.

Development and Validation of an Intratumor Heterogeneity-Based Prognostic Model for Clear Cell Renal Cell Carcinoma.

Journal: JCO precision oncology

Published: December 10, 2025

Predicting immunotherapy benefit in leiomyosarcoma through active chromatin cfDNA profiling.

Predicting immunotherapy benefit in leiomyosarcoma through active chromatin cfDNA profiling.

Journal: NPJ precision oncology

Published: November 04, 2025

Tebentafusp in Metastatic Uveal Melanoma: A Meta-analysis.

Tebentafusp in Metastatic Uveal Melanoma: A Meta-analysis.

Journal: Targeted oncology

Published: August 04, 2025

Identifying predictors of overall survival among patients with TMB-low metastatic cancer treated with immune checkpoint inhibitors.

Identifying predictors of overall survival among patients with TMB-low metastatic cancer treated with immune checkpoint inhibitors.

Journal: The oncologist

Published: October 31, 2024

Discordance Between the Initial Diagnosis of Sarcomas and Subsequent Histopathological Revision and Molecular Analyses in a Sarcoma Reference Center in Brazil.

Discordance Between the Initial Diagnosis of Sarcomas and Subsequent Histopathological Revision and Molecular Analyses in a Sarcoma Reference Center in Brazil.

Journal: JCO global oncology

Published: July 18, 2024

A Comprehensive Exploration of Agents Targeting Tumor Microenvironment: Challenges and Future Perspectives.

A Comprehensive Exploration of Agents Targeting Tumor Microenvironment: Challenges and Future Perspectives.

Journal: Journal of immunotherapy and precision oncology

Published: June 09, 2024

The Clinical and Molecular Profile of Lung Cancer Patients Harboring the TP53 R337H Germline Variant in a Brazilian Cancer Center: The Possible Mechanism of Carcinogenesis.

The Clinical and Molecular Profile of Lung Cancer Patients Harboring the TP53 R337H Germline Variant in a Brazilian Cancer Center: The Possible Mechanism of Carcinogenesis.

Journal: International journal of molecular sciences

Published: August 30, 2023

Interplay between Tumor Mutational Burden and Mutational Profile and Its Effect on Overall Survival: A Pilot Study of Metastatic Patients Treated with Immune Checkpoint Inhibitors.

Interplay between Tumor Mutational Burden and Mutational Profile and Its Effect on Overall Survival: A Pilot Study of Metastatic Patients Treated with Immune Checkpoint Inhibitors.

Journal: Cancers

Published: August 27, 2022

Unique SLC12A2-ROS1 fusion is associated with marked response to crizotinib in lung adenocarcinoma.

Unique SLC12A2-ROS1 fusion is associated with marked response to crizotinib in lung adenocarcinoma.

Journal: SAGE open medical case reports

Published: December 15, 2021

Cardiovascular toxicity following immune checkpoint inhibitors: A systematic review and meta-analysis.

Cardiovascular toxicity following immune checkpoint inhibitors: A systematic review and meta-analysis.

Journal: Translational oncology

Published: November 12, 2021

Extreme Responses to a Combination of DNA-Damaging Therapy and Immunotherapy in CDK12-Altered Metastatic Castration-Resistant Prostate Cancer: A Potential Therapeutic Vulnerability.

Extreme Responses to a Combination of DNA-Damaging Therapy and Immunotherapy in CDK12-Altered Metastatic Castration-Resistant Prostate Cancer: A Potential Therapeutic Vulnerability.

Journal: Clinical genitourinary cancer

Published: October 15, 2021

Showing 1-12 of 13

Last Updated: 09/26/2026